ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

WVE Wave Life Sciences Ltd

6.14
0.26 (4.42%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Wave Life Sciences Ltd NASDAQ:WVE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.26 4.42% 6.14 5.46 6.48 6.3799 5.90 5.93 849,147 01:00:00

Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference

28/05/2021 1:30pm

GlobeNewswire Inc.


Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Wave Life Sciences Charts.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a presentation at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. Dr. Bolno will provide a corporate update and discuss Wave’s pipeline programs, including the first in vivo data from the company’s ADAR editing discovery program for alpha-1 antitrypsin deficiency (AATD).

A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:Kate Rausch617-949-4827krausch@wavelifesci.com

Media Contact:Alicia Suter617-949-4817asuter@wavelifesci.com

1 Year Wave Life Sciences Chart

1 Year Wave Life Sciences Chart

1 Month Wave Life Sciences Chart

1 Month Wave Life Sciences Chart

Your Recent History

Delayed Upgrade Clock